v3.26.1
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Cash flows from operating activities:    
Net income (loss) $ (1,923,297) $ 134,654
Adjustments to reconcile net income (loss) to net cash provided by operating activities:    
Depreciation and amortization 93,416 81,648
Stock-based compensation expense 6,703 6,802
Deferred income taxes (97,472) 12,183
Total Other operating expense (income), net 2,134,660 0
Remeasurement of contingent consideration reserves (2,622) (12,544)
Restructuring charges (10,103) (975)
Other (112) 1,546
Changes in assets and liabilities, net of effect from acquisitions:    
Accounts receivable 22,678 17,979
Prepaids and other current assets 2,382 (5,979)
Accounts payable 4,080 (396)
Accrued compensation (23,204) (14,969)
Deferred revenue 31,492 29,972
Other assets and liabilities 2,277 (1,403)
Net cash provided by operating activities 240,878 248,518
Cash flows from investing activities:    
Purchases of property and equipment (5,095) (3,540)
Capitalization of software development costs (60,271) (66,443)
Acquisitions, net of cash acquired (11,115) (16,751)
Purchases of investments (15,000) 0
Proceeds from divestitures 0 4,136
Other (773) (1,305)
Net cash used in investing activities (92,254) (83,903)
Cash flows from financing activities:    
Proceeds from issuance of term loans 524,420 0
Proceeds from revolving credit facility 149,070 0
Repayment of revolving credit facility (46,500) 0
Debt issuance costs (3,779) 0
Net transfers to Hexagon (16,048) (166,195)
Cash payment to Hexagon in connection with the Distribution (625,000) 0
Payment of contingent consideration (606) 0
Proceeds from other short-term borrowings 22,903 0
Net cash provided by (used in) financing activities 4,460 (166,195)
Effect of foreign exchange rate changes on cash and cash equivalents (5,006) 6,015
Net increase in cash and cash equivalents 148,078 4,435
Cash and cash equivalents at beginning of period 156,069 97,214
Cash and cash equivalents at end of period $ 304,147 $ 101,649